文献速递眼底病与葡萄膜炎

ARMS2/HTRA1基因风险单倍型与年龄相关性黄斑变性的表型病程:EYE-RISK联盟研究

The Phenotypic Course of Age-Related Macular Degeneration for ARMS2/HTRA1: The EYE-RISK Consortium.
PubMed 文献 · Ophthalmology · 2022-03-01

该研究汇总分析了欧洲17 204名55岁及以上个体的遗传与表型数据,发现ARMS2/HTRA1风险单倍型纯合携带者发生晚期年龄相关性黄斑变性(AMD)的风险显著增高,且发病年龄较非风险基因型携带者提前9.6年。该风险单倍型与≥125 μm的软性玻璃膜疣及网状假性玻璃膜疣风险升高相关,纯合携带者脉络膜新生血管(CNV)风险高于补体通路高遗传风险评分者。

要点

  • ARMS2/HTRA1纯合携带者发生地图样萎缩、CNV和混合型晚期AMD的OR分别为8.6、11.2和12.2。
  • 晚期AMD终生累积风险:非风险基因型携带者4.4%,杂合携带者9.4%,纯合携带者26.8%。
  • 纯合携带者确诊晚期AMD的年龄比非风险基因型携带者早9.6年(95%CI 8.0-11.2)。

核心结论

  • ARMS2/HTRA1风险单倍型携带者发生晚期AMD的风险尤其高,且发病年龄相对较早。
  • 数据提示ARMS2/HTRA1风险变异在早期体征出现后是疾病进展的强催化剂。
  • 该风险单倍型的表型谱与补体基因相似,仅CNV风险更高。

研究设计与样本

  • 研究设计为4项病例对照研究和6项队列研究的汇总分析。
  • 研究对象为参与欧洲眼科流行病学联盟的17 204名55岁及以上个体。
  • 采用多模态图像判定AMD特征和黄斑厚度,并统一遗传与表型数据。

主要发现

  • 2 068例晚期AMD患者中,64.7%携带ARMS2/HTRA1风险等位基因。
  • 纯合携带者发生地图样萎缩的OR为8.6(95%CI 6.5-11.4),CNV的OR为11.2(95%CI 9.4-13.3),混合型晚期AMD的OR为12.2(95%CI 7.3-20.6)。
  • 晚期AMD终生累积风险从非风险基因型携带者的4.4%升至杂合携带者的9.4%和纯合携带者的26.8%。
  • 纯合携带者确诊晚期AMD的时间比非风险基因型携带者早9.6年(95%CI 8.0-11.2)。
  • 风险单倍型与<125 μm的硬性或软性玻璃膜疣无显著关联(OR 1.2,95%CI 0.9-1.7),但与≥125 μm软性玻璃膜疣风险显著升高相关(OR 2.1,95%CI 1.5-3.0),网状假性玻璃膜疣的OR达7.2(95%CI 3.8-13.8)。

关键数值与推荐

  • 与补体通路高遗传风险评分者相比,ARMS2/HTRA1纯合携带者的CNV风险更高(OR 4.1,95%CI 3.2-5.4),其他特征风险无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Age-related maculopathy susceptibility 2 (ARMS2) is considered the most enigmatic of the genes for age-related macular degeneration (AMD). We investigated the phenotypic course and spectrum of AMD for the risk haplotype at the ARMS2 and high-temperature requirement A serine peptidase 1 (HTRA1) locus in a large European consortium. DESIGN: Pooled analysis of 4 case-control and 6 cohort studies. PARTICIPANTS: Individuals (N = 17 204) aged 55 years or older participating in the European Eye Epidemiology consortium. METHODS: Age-related macular degeneration features and macular thickness were determined on multimodal images; data on genetics and phenotype were harmonized. Risks of AMD features for rs3750486 genotypes at the ARMS2/HTRA1 locus were determined by logistic regression and were compared with a genetic risk score (GRS) of 19 variants at the complement pathway. Lifetime risks were estimated with Kaplan-Meier analyses in population-based cohorts. MAIN OUTCOME MEASURES: Age-related macular degeneration features and stage. RESULTS: Of 2068 individuals with late AMD, 64.7% carried the ARMS2/HTRA1 risk allele. For homozygous carriers, the odds ratio (OR) of geographic atrophy was 8.6 (95% confidence interval [CI], 6.5-11.4), of choroidal neovascularization (CNV) was 11.2 (95% CI, 9.4-13.3), and of mixed late AMD was 12.2 (95% CI, 7.3-20.6). Cumulative lifetime risk of late AMD ranged from 4.4% for carriers of the nonrisk genotype to 9.4% and 26.8% for heterozygous and homozygous carriers. The latter received the diagnosis of late AMD 9.6 years (95% CI, 8.0-11.2) earlier than carriers of the nonrisk genotype. The risk haplotype was not associated with hard or soft drusen < 125 μm (OR, 1.2; 95% CI, 0.9-1.7), but risks increased significantly for soft drusen ≥ 125 μm (OR, 2.1; 95% CI, 1.5-3.0), up to an OR of 7.2 (95% CI, 3.8-13.8) for reticular pseudodrusen. Compared with persons with a high GRS for complement, homozygous carriers of ARMS2/HTRA1 showed a higher risk of CNV (OR, 4.1; 95% CI, 3.2-5.4); risks of other characteristics were not different. CONCLUSIONS: Carriers of the risk haplotype at ARMS2/HTRA1 have a particularly high risk of late AMD at a relatively early age. Data suggest that risk variants at ARMS2/HTRA1 act as a strong catalyst of progression once early signs are present. The phenotypic spectrum resembles that of complement genes, only with higher risks of CNV.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Thee EF, Colijn JM, Cougnard-Grégoire A, et al. The Phenotypic Course of Age-Related Macular Degeneration for ARMS2/HTRA1: The EYE-RISK Consortium. Ophthalmology. 2022. PMID: 35240203. doi:10.1016/j.ophtha.2022.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。